title: Survey of susceptibility to marbofloxacin in bacteria isolated from diseased pigs in Europe.
abstract: A monitoring programme of marbofloxacin susceptibility of bacteria from Europe causing respiratory tract infection and meningitis in pigs has been active since 1994 and 2002, respectively. Monitoring digestive, metritis and urinary tract infection (UTI) in pigs has been active since 2005 and susceptibility results until 2013 are presented. Minimum inhibitory concentration (MIC) was determined by broth microdilution. For MIC interpretation, Vétoquinol-evaluated breakpoints were applied. For digestive pathogens,Escherichia coliandSalmonellaspecies (1717 and 300 isolates, respectively) exhibited 7.5 per cent resistance inE coliand no resistance inSalmonellaspecies. Similarly,E colifrom metritis (369 isolates) had 7.0 per cent resistance to marbofloxacin. However,E colifrom UTI (633 isolates) had higher resistance (10.4 per cent). ForStreptococcus suiscausing meningitis (585 isolates), marbofloxacin susceptibility was very high with only 0.5 per cent resistance and 0.4 per cent resistance was observed withS suiscausing respiratory disease (729 isolates). Other respiratory pathogens were also highly susceptible to marbofloxacin with no resistance inActinobacillus pleuropneumoniae(647 isolates) orBordetella bronchiseptica(504 isolates), 0.1 per cent resistance inPasteurella multocida(1373 isolates) and 1.4 per cent resistance inHaemophilus parasuis(145 isolates). There was no apparent change in marbofloxacin MIC over time for any bacterial pathogen based on MIC50/90These data confirm previously published MIC results from porcine and other animal infections.
authors.affiliation: Vétoquinol S.A., Global Drug Development, 34 rue du Chêne Sainte Anne, Lure 70200, France.
authors.forename: F
authors.initials: F
authors.lastname: El Garch
authors.affiliation: Vétoquinol S.A., Global Drug Development, 34 rue du Chêne Sainte Anne, Lure 70200, France.
authors.forename: S
authors.initials: S
authors.lastname: Kroemer
authors.affiliation: Vétoquinol S.A., Global Drug Development, 34 rue du Chêne Sainte Anne, Lure 70200, France.
authors.forename: D
authors.initials: D
authors.lastname: Galland
authors.affiliation: IHMA Europe Sàrl, Rte de l'Ile-au-Bois 1A, Monthey/VS 1870, Switzerland.
authors.forename: I
authors.initials: I
authors.lastname: Morrissey
authors.affiliation: Vétoquinol S.A., Global Drug Development, 34 rue du Chêne Sainte Anne, Lure 70200, France.
authors.forename: F
authors.initials: F
authors.lastname: Woehrle
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy / Q000662:veterinary*; D024881:Drug Resistance, Bacterial; D005060:Europe; D024841:Fluoroquinolones / Q000494:pharmacology* / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C080260:marbofloxacin
keywords: Antimicrobials; Pigs; Resistance